Is there an age limit for thrombolytic therapy?

Area of Science:

• Cardiology
• Emergency Medicine
• Geriatrics

Background:

• Acute myocardial infarction (heart attack) poses a significant mortality risk, particularly in patients over 65 years old.
• One-month mortality rates for elderly heart attack patients range from 20-30%.
• Thrombolytic therapy has emerged as a critical intervention for acute myocardial infarction.

Purpose of the Study:

• To evaluate the efficacy and safety of thrombolytic therapy in patients with acute myocardial infarction, with a focus on the elderly population.
• To assess the risk-benefit profile of thrombolytic treatment in older adults compared to younger patients.

Main Methods:

• The study analyzes data on patients undergoing thrombolytic therapy for acute myocardial infarction.
• Outcomes including mortality, stroke rates (hemorrhagic and ischemic), infarct size, and subsequent morbidity (heart failure, arrhythmias) are examined.
• Comparisons are made between different age groups, specifically focusing on individuals over 65.

Main Results:

• Thrombolytic therapy demonstrates substantial mortality benefits in acute myocardial infarction patients, including those over 65.
• While the proportional benefit is less in older patients, the absolute benefit is comparable or greater due to higher baseline mortality.
• The risk of stroke is slightly increased (1-2 per 1,000) due to a balance between increased cerebral hemorrhage and decreased ischemic/embolic stroke, but this is offset by approximately 20 fewer deaths per 1,000 myocardial infarctions.

Conclusions:

• Thrombolytic therapy offers significant survival advantages in acute myocardial infarction, even in elderly patients.
• The treatment leads to reduced infarct size and decreased morbidity from complications like heart failure and arrhythmias.
• The observed trade-off in stroke risk is acceptable given the substantial reduction in overall mortality.